Simon P. Fricker

机构：Phio Pharmaceuticals (United States)

发表论文 127 篇 · 总被引 6120 次 · h-index 34

代表论文

• Self-delivering RNAi immunotherapeutic PH-762 silences PD-1 to generate local and abscopal antitumor efficacy (2024 · Frontiers in Immunology · 被引 5)
• Abstract 5113: INTASYL self-delivering RNAi therapeutic dual targeting PD-1 and CTLA-4 provides synergistic antitumor efficacy in the treatment of murine colon cancer in vivo (2023 · Cancer Research · 被引 3)
• Abstract 1846: Intratumoral mPH-762, a self-delivering RNAi therapeutic (INTASYL™) targeting mouse PD-1, generates systemic tumor-specific memory CD8 T cells, providing a mechanism for abscopal efficacy toward untreated tumors in a murine hepatocarcinoma model (2023 · Cancer Research · 被引 1)
• 599 New checkpoints controlling function of cytotoxic lymphocytes infiltrating human carcinoma (2020 · Regular and Young Investigator Award Abstracts · 被引 1)
• Abstract 2239: Intratumoral delivery of mPH-804 (TIGIT targeting INTASYL compound) inhibits tumor growth and confers an inflammatory tumor microenvironment (2020 · Cancer Research · 被引 1)
• Abstract PO-037: Machine learning-enabled transomics identifies three therapeutic targets for MYC-driven diffuse large B cell lymphoma (2024 · Blood Cancer Discovery)